David Kyle, DO
General Practice · Los Angeles, CANPI 1952531758
Payments from drug & device makers
Across 111 payments — averaging $36.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$2K
- Lilly USA, LLC$432
- Johnson & Johnson$206
- Biohaven Pharmaceutical Holding Company Ltd.$196
- Boehringer Ingelheim$145
- AbbVie$125
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,005100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 8 | $1,742 |
| Lilly USA, LLC | 17 | $432 |
| Johnson & Johnson | 5 | $206 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $196 |
| Boehringer Ingelheim | 8 | $145 |
| AbbVie | 6 | $125 |
| Pfizer | 6 | $114 |
| BD | 4 | $103 |
| Novartis | 5 | $99 |
| Novo Nordisk | 5 | $94 |
| Biohaven Pharmaceuticals, Inc. | 5 | $92 |
| Revance Therapeutics, Inc. | 1 | $89 |
| AstraZeneca | 5 | $87 |
| Scilex Pharmaceuticals Inc. | 5 | $86 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| GSK | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Qiagen, LLC | 1 | $19 |
| Amgen | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,005 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $197,720 |
| JardianceEmpagliflozin | 82 | $80,363 |
| OpzeluraRuxolitinib Phosphate | 15 | $60,293 |
| JanuviaSitagliptin Phosphate | 64 | $49,942 |
| Xtampza ErOxycodone Myristate | 45 | $46,244 |
| Nurtec OdtRimegepant Sulfate | 44 | $44,648 |
| EliquisApixaban | 60 | $41,000 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $30,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $28,387 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,022 | $22,909 |
| Ondansetron Hcl | 62 | $22,882 |
| VemlidyTenofovir Alafenamide | 13 | $21,367 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $20,007 |
| OxycontinOxycodone Hcl | 27 | $19,638 |
| MyrbetriqMirabegron | 35 | $18,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $94 | $197,720166 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $145 | $98,836114 claims |
| PfizerNurtec Odt, Eliquis | $114 | $85,648104 claims |
| MerckJanuvia | $22 | $49,94264 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $29 | $48,39479 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $33 | $46,24445 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $87 | $35,71456 claims |
| Lilly USA, LLCMounjaro | $432 | $16,55913 claims |
| Johnson & JohnsonXarelto | $206 | $15,75419 claims |
| NovartisEntresto | $99 | $11,26511 claims |
| Redhill Biopharma Inc.Movantik | $23 | $4,60311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Los Angeles
- Bruce TorkanLos Angeles$3.8M
- Abdi SameniLos Angeles$316K
- Enrique GonzalezLos Angeles$303K
- Kent HwangLos Angeles$290K
- Kyle StanleyLos Angeles$259K
- Yang ChaiLos Angeles$150K
- Richard KimLos Angeles$97K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.